Mark Vignola
Director of Finance/CFO at TERNS PHARMACEUTICALS, INC.
Net worth: 571 697 $ as of 2024-03-30
Profile
Mark J.
Vignola is currently the Chief Financial Officer & Treasurer at Terns Pharmaceuticals, Inc. He previously worked as an Analyst at Lehman Brothers, Inc. from 1999 to 2000.
From 2015 to 2019, he served as the Head-Corporate Development at Intercept Pharmaceuticals, Inc. Prior to that, he was an Equity Research Associate at Needham & Co. LLC from 2011 to 2015.
He also worked as a Research Assistant at Duke University Medical Center from 2003 to 2011.
In 2019, he held the position of Chief Financial Officer at Applied Therapeutics, Inc. Dr. Vignola obtained his graduate degree from Duke University in 2002 and his undergraduate degree from Boston College in 1999.
He also holds a doctorate degree from Duke University School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-22 | 87,149 ( 0.13% ) | 571 697 $ | 2024-03-30 |
Mark Vignola active positions
| Companies | Position | Start |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Director of Finance/CFO | 2020-08-10 |
Former positions of Mark Vignola
| Companies | Position | End |
|---|---|---|
| APPLIED THERAPEUTICS, INC. | Director of Finance/CFO | 2020-04-30 |
| INTERCEPT PHARMACEUTICALS, INC. | Investor Relations Contact | 2019-04-30 |
Needham & Co. LLC
 Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Analyst-Equity | 2015-04-30 |
| Duke University Medical Center | Corporate Officer/Principal | 2010-12-31 |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Corporate Officer/Principal | 1999-12-31 |
Training of Mark Vignola
| Duke University | Graduate Degree |
| Boston College | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| APPLIED THERAPEUTICS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Needham & Co. LLC
Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Finance |
- Stock Market
- Insiders
- Mark Vignola
